APA (7th ed.) Citation

A, C., M, D., F, R., N, G., M, S., I, L., . . . G, Z. (2025). JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib. British journal of haematology, 206(2), 758. https://doi.org/10.1111/bjh.19979

Chicago Style (17th ed.) Citation

A, Ceccardi, et al. "JAK2 Is a Critical Therapeutic Target in VEXAS Syndrome Treated with Ruxolitinib." British Journal of Haematology 206, no. 2 (2025): 758. https://doi.org/10.1111/bjh.19979.

MLA (9th ed.) Citation

A, Ceccardi, et al. "JAK2 Is a Critical Therapeutic Target in VEXAS Syndrome Treated with Ruxolitinib." British Journal of Haematology, vol. 206, no. 2, 2025, p. 758, https://doi.org/10.1111/bjh.19979.